Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Cisplatin
Related studies linked through entity extraction aliases.
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
- Status
- COMPLETED
- Phase
- PHASE3
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Pathological Response After Neoadjuvant Treatment on NSCLC
- Status
- RECRUITING
- Phase
- N/A